A phase II exploratory trial (UMIN-000008379) of a peptide-derived vaccine containing a mix of three CTAs (LY6K, CDCA1, and IMP3) and Montanide ISA51, in a cohort of 37 patients with LA or R/M HNSCC, reported a better clinical response and longer survival than the cohort (n = 18) that included HLA-A24 negative patients who were receiving best supportive care [120]. Here, LY6K is linked to head and neck squamous cell carcinoma.